Navigation Links
Pfizer Whistleblower Named Year's Most Influential Person In Business Ethics
Date:12/18/2009

WASHINGTON, Dec. 18 /PRNewswire-USNewswire/ -- John Kopchinski, the whistleblower whom Phillips & Cohen LLP represented in a successful, record-setting "qui tam" case against Pfizer Inc., has been named as the most influential person in business ethics for 2009.

Ethisphere, a think tank that focuses on business ethics, corporate social responsibility, anti-corruption and sustainability, compiles an annual list of the 100 most influential people in business ethics. The group named Kopchinski number one on its 2009 list.

A former sales representative for Pfizer, Kopchinski exposed the company's illegal sales and marketing campaign for the prescription painkiller Bextra for uses and in doses that endangered patients' health and lives. (See http://www.phillipsandcohen.com/CM/NewsSettlements/NewsSettlements531.asp)

Pfizer paid $1.8 billion in September to the government to settle Kopchinski's qui tam lawsuit and a related criminal charge. The company settled four other whistleblower lawsuits at the same time, bringing the total settlement to $2.3 billion. It was the largest healthcare fraud settlement ever and the largest criminal fine ever imposed in the U.S.

"John Kopchinski wasn't seen as a team player and ultimately lost his job at Pfizer," said Erika Kelton, a Washington, DC, attorney with Phillips & Cohen. "But the happy ending to his story and the recognition this honor bestows should give other whistleblowers hope."

Kopchinski "officially turned whistleblowing into big business," said Ethisphere. He received more than $70 million as a reward for the work he and his attorneys did on the Pfizer case. The False Claims Act requires the government to award whistleblowers a percentage of the funds the government recovers as a result of their qui tam cases.

Phillips & Cohen specializes in representing whistleblowers in cases involving fraud against the government, tax matters and securities violations. Cases brought by the firm's attorneys have recovered more than $5.3 billion in civil and criminal penalties for the government. For more information about whistleblowers and qui tam cases, see www.phillipsandcohen.com.

For more information about the Pfizer qui tam case and settlement, see http://www.phillipsandcohen.com/CM/NewsSettlements/NewsSettlements536.asp

SOURCE Phillips & Cohen LLP


'/>"/>
SOURCE Phillips & Cohen LLP
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):